Carlina Develops Anticancer Nanocapsules For Pets And Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
French drug delivery firm Carlina is developing new lipid-based nanoparticle formulations of cancer drugs for pets and patients, and aims to build a proprietary pipeline with the help of collaborations with other companies.
You may also be interested in...
Nanobiotix's IPO Triggers Calls In Europe For More "Citizen Funding"
Nanotechnology which amplifies the antitumor effects of radiotherapy is being developed by French company Nanobiotix, which has just completed an IPO on NYSE Euronext in Paris, following investment by the general public in France via citizen's funds.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.